EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Borderline tumours of the ovary: A 37‐year experience at a tertiary referral centre

Rosie McBain, Aidan Kashyap, Milly Bishop, Estefania Vicario, Mila Volchek, Yael Naaman, Niveditha Rajadevan, Antonia Jones, Deborah Neesham, Orla McNally

Australian and New Zealand Journal of Obstetrics and Gynaecology · 2025-02 · 65 (1) · 163-172

DOI: 10.1111/ajo.13876 ↗
AbstractBibliografische Angaben

Abstract

Introduction Borderline ovarian tumours ( BOT ) are a common epithelial ovarian tumours. Typically diagnosed at an early stage with a good prognosis, many BOT are treated conservatively. Recurrence is common. This update to our last audit in 1997 represents one of the largest audits of BOT to date. Materials and Methods All patients with BOT managed at ‘the hospital’ from 1984 to 2021 were included. Expert pathology review was available. Results There were 549 cases included. The recurrence rate was 5% ( n = 29/549) with 1.4% ( n = 8/549) undergoing malignant transformation. Three of the eight women who recurred as cancer died from their disease. Frozen section was predictive of histologic diagnosis in 92% ( n = 55/60) of serous tumours (SBOT), but only 62% ( n = 54/87) of mucinous tumours (MBOT). In MBOT where the appendix appeared normal intra‐operatively, it was histologically benign in all cases ( n = 63). In SBOT, the recurrence rate was 5/23 (22%), 12/52 (23%), 1/29 (3%) and 3% ( P =

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →